174635-69-9

中文名稱 3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺

英文名稱 SB 222200

CAS 174635-69-9

分子式 C26H24N2O

分子量 380.48

MOL 文件 174635-69-9.mol

更新日期 2024/11/15 18:20:33

174635-69-9 結(jié)構(gòu)式

基本信息物理化學(xué)性質(zhì) 安全數(shù)據(jù) 圖譜信息 3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺價(jià)格(試劑級(jí)) 常見問(wèn)題列表

基本信息

中文別名

3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺

英文別名

CS-1124
SB 222200
SB-222200
SB222200
(S)-3-METHYL-2-PHENYL-N-(1-PHENYLPROPYL)-4-QUINOLINECARBOXAMIDE
3-Methyl-2-phenyl-N-((1S)-1-phenylpropyl)quinoline-4-carboxamide
3-METHYL-2-PHENYL-N-[(1S)-1-PHENYLPROPYL]-4-QUINOLINECARBOXAMIDE
4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]-
SB222200//3-Methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxaMide

物理化學(xué)性質(zhì)

熔點(diǎn)154℃

沸點(diǎn)553.5±50.0 °C(Predicted)

密度1.142

儲(chǔ)存條件Sealed in dry,2-8°C

溶解度DMSO: ~28 mg/mL, soluble

溶解度DMSO：~28 mg/mL，可溶

酸度系數(shù)(pKa)12.88±0.46(Predicted)

形態(tài)solid

顏色light yellow

InChI1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1

InChIKeyMQNYRKWJSMQECI-QFIPXVFZSA-N

SMILESCC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c3ccccc3)c4ccccc4

安全數(shù)據(jù)

安全說(shuō)明22-24/25

WGK Germany3

存儲(chǔ)類別11 - Combustible Solids

圖譜信息

3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺(174635-69-9)核磁圖(¹HNMR)

3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺價(jià)格(試劑級(jí))

報(bào)價(jià)日期	產(chǎn)品編號(hào)	產(chǎn)品名稱	CAS號(hào)	包裝	價(jià)格
2026/06/05	HY-15722	3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺 SB-222200	174635-69-9	5 mg	755元
2026/06/05	HY-15722	3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺 SB-222200	174635-69-9	10mM * 1mLin DMSO	830元
2026/06/05	HY-15722	3-甲基-2-苯基-N-((1S)-1-苯基丙基)喹啉-4-甲酰胺 SB-222200	174635-69-9	10mg	1171元

常見問(wèn)題列表

生物活性

SB-222200 是一種有效、選擇性、口服活性的，具有血腦屏障 (BBB) 滲透性的 NK-3 受體 (NK-3 receptor) 拮抗劑。SB-222200 被開發(fā)用于中樞神經(jīng)系統(tǒng)疾病的研究。

靶點(diǎn)

NK3

體外研究

SB-222200 inhibits ¹²⁵ I-[MePhe ⁷ ]neurokinin B (NKB) binding to CHO cell membranes stably expressing the hNK-3 receptor (CHO-hNK-3R) with a K _i of 4.4 nM and antagonizes NKB-induced Ca ²⁺ mobilization in HEK 293 cells stably expressing the hNK-3 receptor (HEK 293-hNK-3R) with an IC ₅₀ of 18.4 nM.
SB-222200 is selective for hNK-3 receptors compared with hNK-1 (K _i >100,000 nM) and hNK-2 receptors (K _i =250 nM).
SB-222200 (10 nM-1 μM) produces a concentration-dependent, surmountable inhibition of NKB-induced Ca ²⁺ mobilization in HEK 293-hNK-3R cells.

體內(nèi)研究

SB-222200 (5 mg/kg; 30 min pretreatment) produces inhibition of behavioral responses induced by NK-3 receptor-selective agonist senktide (HY-P0187) in mice.
SB-222200 exhibits terminal elimination half-lives (rat about 2 h) and high systemic plasma clearance (56 mL/min/kg), with a moderately large volume of distribution (3-5 L/kg).

Animal Model:	Male BALB/c mice (19-21 g)
Dosage:	5 mg/kg
Administration:	Oral administration
Result:	Produced 57% inhibition of senktide-induced behavioral responses in mice.

Animal Model:	Male Sprague-Dawley rats (300-400 g)
Dosage:	2.5 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis)
Administration:	Intravenous injection and oral gavage
Result:	Oral bioavailability (46%), T _1/2 (2.4 h for i.v.; 2.1 h for p.o.), C _max (427 ng/mL).